​

VistaGen Therapeutics (VTGN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

VTGN Stock Forecast

VistaGen Therapeutics (VTGN) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $6.00, with a high of $6.00 and a low of $6.00. This represents a 135.29% increase from the last price of $2.55.

High: $6 Avg: $6 Low: $6 Last Closed Price: $2.55

VTGN Stock Rating

VistaGen Therapeutics stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (71.43%), 2 Hold (28.57%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 2 5 Strong Sell Sell Hold Buy Strong Buy

VTGN Price Target Upside V Benchmarks

TypeNameUpside
StockVistaGen Therapeutics135.29%
SectorHealthcare Stocks 29.84%
IndustryBiotech Stocks 74.53%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$2.55$2.55$2.55
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
May, 2513---4
Apr, 2513---4
Mar, 2513---4
Feb, 2513---4
Jan, 2513---4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 22, 2022Andrew TsaiJefferies$6.00$4.3836.99%135.29%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 07, 2023Maxim GroupBuyupgrade
Apr 26, 2022Zacks Investment ResearchHolddowngrade
Feb 18, 2021JefferiesBuyinitialise

Financial Forecast

EPS Forecast

$-15 $-11 $-7 $-3 $1 $5 Mar 21 Mar 22 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 21Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$-6.25$-7.24$-8.51$-1.52-----
Avg Forecast$-6.38$-6.68$-8.40$-1.60$-1.83$-1.90$-2.05$-1.01$1.23
High Forecast$-2.05$-2.14$-4.96$-1.50$-1.77$-1.34$-1.62$-0.60$2.18
Low Forecast$-13.49$-14.12$-14.87$-1.78$-1.88$-2.85$-2.44$-1.79$0.73
Surprise %-2.04%8.38%1.31%-5.00%-----

Revenue Forecast

$-50M $50M $150M $250M $350M $450M Mar 21 Mar 22 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 21Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$1.09M$1.11M$-227.30K$1.06M-----
Avg Forecast$877.30K$1.32M$-403.00K$1.07M$689.33K$632.65K$6.94M$69.85M$260.38M
High Forecast$1.63M$2.46M$-276.03K$1.21M$1.34M$1.01M$11.05M$111.24M$414.64M
Low Forecast$419.24K$632.93K$-641.76K$849.62K$268.57K$433.32K$4.75M$47.84M$178.34M
Surprise %24.19%-16.28%-43.60%-0.26%-----

Net Income Forecast

$-300M $-230M $-160M $-90M $-20M $50M Mar 21 Mar 22 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 21Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$-17.93M$-47.76M$-59.25M$-29.36M-----
Avg Forecast$-123.38M$-129.19M$-162.58M$-32.07M$-35.37M$-40.61M$-39.29M$-19.55M$23.81M
High Forecast$-39.64M$-41.50M$-95.99M$-28.94M$-34.31M$-25.98M$-31.35M$-11.54M$42.14M
Low Forecast$-261.07M$-273.36M$-287.80M$-34.49M$-36.42M$-55.23M$-47.22M$-34.60M$14.06M
Surprise %-85.46%-63.03%-63.56%-8.45%-----

VTGN Forecast FAQ

Is VistaGen Therapeutics stock a buy?

VistaGen Therapeutics stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that VistaGen Therapeutics is a favorable investment for most analysts.

What is VistaGen Therapeutics's price target?

VistaGen Therapeutics's price target, set by 7 Wall Street analysts, averages $6 over the next 12 months. The price target range spans from $6 at the low end to $6 at the high end, suggesting a potential 135.29% change from the previous closing price of $2.55.

How does VistaGen Therapeutics stock forecast compare to its benchmarks?

VistaGen Therapeutics's stock forecast shows a 135.29% upside, outperforming the average forecast for the healthcare stocks sector (29.84%) and outperforming the biotech stocks industry (74.53%).

What is the breakdown of analyst ratings for VistaGen Therapeutics over the past three months?

  • May 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is VistaGen Therapeutics’s EPS forecast?

VistaGen Therapeutics's average annual EPS forecast for its fiscal year ending in March 2025 is $-1.83, marking a 20.39% increase from the reported $-1.52 in 2024. Estimates for the following years are $-1.9 in 2026, $-2.05 in 2027, $-1.01 in 2028, and $1.23 in 2029.

What is VistaGen Therapeutics’s revenue forecast?

VistaGen Therapeutics's average annual revenue forecast for its fiscal year ending in March 2025 is $689.33K, reflecting a -35.21% decrease from the reported $1.06M in 2024. The forecast for 2026 is $632.65K, followed by $6.94M for 2027, $69.85M for 2028, and $260.38M for 2029.

What is VistaGen Therapeutics’s net income forecast?

VistaGen Therapeutics's net income forecast for the fiscal year ending in March 2025 stands at $-35.366M, representing an 20.46% increase from the reported $-29.358M in 2024. Projections indicate $-40.606M in 2026, $-39.29M in 2027, $-19.548M in 2028, and $23.81M in 2029.